BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 35416967)

  • 1. Vulvovaginal Candidiasis: A Review of the Evidence for the 2021 Centers for Disease Control and Prevention of Sexually Transmitted Infections Treatment Guidelines.
    Nyirjesy P; Brookhart C; Lazenby G; Schwebke J; Sobel JD
    Clin Infect Dis; 2022 Apr; 74(Suppl_2):S162-S168. PubMed ID: 35416967
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis: Design, Development and Place in Therapy.
    Phillips NA; Rocktashel M; Merjanian L
    Drug Des Devel Ther; 2023; 17():363-367. PubMed ID: 36785761
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence of vulvovaginal candidiasis among pregnant women in the Ho municipality, Ghana: species identification and antifungal susceptibility of Candida isolates.
    Waikhom SD; Afeke I; Kwawu GS; Mbroh HK; Osei GY; Louis B; Deku JG; Kasu ES; Mensah P; Agede CY; Dodoo C; Asiamah EA; Tampuori J; Korbuvi J; Opintan JA
    BMC Pregnancy Childbirth; 2020 May; 20(1):266. PubMed ID: 32375724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [INVESTIGATION ON ANTIFUNGAL SUSCEPTIBILITY OF CANDIDA YEASTS IN PREGNANT PATIENTS WITH CONFIRMED VULVOVAGINAL CANDIDIASIS AND THEIR NEWBORNS.].
    Chokoeva A; Kouzmanov A; Ivanova Z; Zisova L; Amalie G; Petleshkova P; Miteva-Katrandzhieva T; Krasteva M; Uchikova E
    Akush Ginekol (Sofiia); 2016; 55(4):20-29. PubMed ID: 29370489
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interventions for prevention and treatment of vulvovaginal candidiasis in women with HIV infection.
    Ray A; Ray S; George AT; Swaminathan N
    Cochrane Database Syst Rev; 2011 Aug; (8):CD008739. PubMed ID: 21833970
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of Vulvovaginal Candidiasis-An Overview of Guidelines and the Latest Treatment Methods.
    Satora M; Grunwald A; Zaremba B; Frankowska K; Żak K; Tarkowski R; Kułak K
    J Clin Med; 2023 Aug; 12(16):. PubMed ID: 37629418
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of vulvovaginal candidiasis: a review of the literature.
    Dovnik A; Golle A; Novak D; Arko D; Takač I
    Acta Dermatovenerol Alp Pannonica Adriat; 2015; 24(1):5-7. PubMed ID: 25770305
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ibrexafungerp in the Treatment of Vulvovaginal Candidiasis.
    Barnes KN; Yancey AM; Forinash AB
    Ann Pharmacother; 2023 Jan; 57(1):99-106. PubMed ID: 35502451
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence of Candida glabrata and its response to boric acid vaginal suppositories in comparison with oral fluconazole in patients with diabetes and vulvovaginal candidiasis.
    Ray D; Goswami R; Banerjee U; Dadhwal V; Goswami D; Mandal P; Sreenivas V; Kochupillai N
    Diabetes Care; 2007 Feb; 30(2):312-7. PubMed ID: 17259500
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fluconazole-Resistant Candida albicans Vaginal Infections at a Referral Center and Treated With Boric Acid.
    File B; Sobel R; Becker M; Nyirjesy P
    J Low Genit Tract Dis; 2023 Jul; 27(3):262-265. PubMed ID: 36961480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oteseconazole versus fluconazole for the treatment of severe vulvovaginal candidiasis: a multicenter, randomized, double-blinded, phase 3 trial.
    Wang X; Chen L; Ruan H; Xiong Z; Wang W; Qiu J; Song W; Zhang C; Xue F; Qin T; Zhang B; An R; Luo X; Wang W; Zhang S; Cai Y; Kang J; Deng H; Fan S; Cui M; Wang S; Luo X; Su Z; Shu J; Wang Q; Wang F; Bai J; Liao Q
    Antimicrob Agents Chemother; 2024 Jan; 68(1):e0077823. PubMed ID: 38095426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral Ibrexafungerp: an investigational agent for the treatment of vulvovaginal candidiasis.
    Azie N; Angulo D; Dehn B; Sobel JD
    Expert Opin Investig Drugs; 2020 Sep; 29(9):893-900. PubMed ID: 32746636
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pulsatilla decoction inhibits vulvovaginal Candida albicans proliferation and reduces inflammatory cytokine levels in vulvovaginal candidiasis mice].
    Xia D; Zhang M; Shi G; Xu Z; Wu D; Shao J; Wang T; Wang C
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2016 Feb; 32(2):153-7. PubMed ID: 26927371
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phytolectin nanoconjugates in combination with standard antifungals curb multi-species biofilms and virulence of vulvovaginal candidiasis (VVC) causing Candida albicans and non-albicans Candida.
    Senthilganesh J; Kuppusamy S; Durairajan R; Subramaniyan SB; Veerappan A; Paramasivam N
    Med Mycol; 2022 Jan; 60(2):. PubMed ID: 34958385
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A cost-effectiveness analysis of the use of oral ibrexafungerp versus fluconazole for acute vulvovaginal candidiasis in the UK NHS primary care service.
    Shah V; Cyril A; Koleoso P; Ragutharan A; Faiz M; Pushpakanthan P
    Br J Gen Pract; 2024 Jun; 74(suppl 1):. PubMed ID: 38902100
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mrr2 mutations and upregulation are associated with increased fluconazole resistance in Candida albicans isolates from patients with vulvovaginal candidiasis.
    Feng W; Yang J; Ji Y; Xi Z; Yang L; Zhu X; Ma Y
    Lett Appl Microbiol; 2020 Feb; 70(2):95-101. PubMed ID: 31705810
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vulvovaginal candidiasis and asymptomatic vaginal colonization in Portugal: Epidemiology, risk factors and antifungal pattern.
    Fernandes Â; Azevedo N; Valente A; Dias M; Gomes A; Nogueira-Silva C; Henriques M; Silva S; Gonçalves B
    Med Mycol; 2022 May; 60(5):. PubMed ID: 35482711
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Guideline: vulvovaginal candidosis (AWMF 015/072), S2k (excluding chronic mucocutaneous candidosis).
    Mendling W; Brasch J; Cornely OA; Effendy I; Friese K; Ginter-Hanselmayer G; Hof H; Mayser P; Mylonas I; Ruhnke M; Schaller M; Weissenbacher ER
    Mycoses; 2015 Mar; 58 Suppl 1():1-15. PubMed ID: 25711406
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current treatment options for vulvovaginal candidiasis caused by azole-resistant Candida species.
    Sobel JD; Sobel R
    Expert Opin Pharmacother; 2018 Jun; 19(9):971-977. PubMed ID: 29932786
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quercetin Assists Fluconazole to Inhibit Biofilm Formations of Fluconazole-Resistant Candida Albicans in In Vitro and In Vivo Antifungal Managements of Vulvovaginal Candidiasis.
    Gao M; Wang H; Zhu L
    Cell Physiol Biochem; 2016; 40(3-4):727-742. PubMed ID: 27915337
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.